These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 15670034)

  • 1. A potential pharmacogenomic strategy for anticoagulant treatment in non-ST elevation acute coronary syndromes: the role of interleukin-1 receptor antagonist genotype.
    Ray KK; Francis S; Crossman DC
    J Thromb Haemost; 2005 Feb; 3(2):287-91. PubMed ID: 15670034
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low-molecular-weight heparin compared with unfractionated heparin for patients with non-ST-segment elevation acute coronary syndromes treated with glycoprotein IIb/IIIa inhibitors: results from the CRUSADE initiative.
    Singh KP; Roe MT; Peterson ED; Chen AY; Mahaffey KW; Goodman SG; Harrington RA; Smith SC; Gibler WB; Ohman EM; Pollack CV;
    J Thromb Thrombolysis; 2006 Jun; 21(3):211-20. PubMed ID: 16683212
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic variation at the interleukin-1 locus is a determinant of changes in soluble endothelial factors in patients with acute coronary syndromes.
    Ray KK; Camp NJ; Bennett CE; Francis SE; Crossman DC
    Clin Sci (Lond); 2002 Sep; 103(3):303-10. PubMed ID: 12193156
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination of low molecular weight heparins with antiplatelet agents in non-ST elevation acute coronary syndromes: an update.
    Cohen M
    Drugs; 2002; 62(12):1755-70. PubMed ID: 12149045
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Non-ST-segment elevation acute coronary syndrome in patients with renal dysfunction: benefit of low-molecular-weight heparin alone or with glycoprotein IIb/IIIa inhibitors on outcomes. The Global Registry of Acute Coronary Events.
    Collet JP; Montalescot G; Agnelli G; Van de Werf F; Gurfinkel EP; López-Sendón J; Laufenberg CV; Klutman M; Gowda N; Gulba D;
    Eur Heart J; 2005 Nov; 26(21):2285-93. PubMed ID: 15932908
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low molecular weight heparins versus unfractionated heparin for acute coronary syndromes.
    Magee KD; Sevcik W; Moher D; Rowe BH
    Cochrane Database Syst Rev; 2003; (1):CD002132. PubMed ID: 12535430
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Non-ST elevation acute coronary syndrome: changes of parameters of hemostasis during and after treatment with unfractionated heparin and enoxaparin].
    Averkov OV; Slavina NN; Dobrovol'skiĭ AB; Gratsianskiĭ NA
    Kardiologiia; 2003; 43(9):28-40. PubMed ID: 14593367
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: a meta-analysis.
    Eikelboom JW; Anand SS; Malmberg K; Weitz JI; Ginsberg JS; Yusuf S
    Lancet; 2000 Jun; 355(9219):1936-42. PubMed ID: 10859038
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost effectiveness of anticoagulation in acute coronary syndromes.
    Latour-Pérez J; de-Miguel-Balsa E
    Pharmacoeconomics; 2012 Apr; 30(4):303-21. PubMed ID: 22409291
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of effects on markers of blood cell activation of enoxaparin, dalteparin, and unfractionated heparin in patients with unstable angina pectoris or non-ST-segment elevation acute myocardial infarction (the ARMADA study).
    Montalescot G; Bal-dit-Sollier C; Chibedi D; Collet JP; Soulat T; Dalby M; Choussat R; Cohen A; Slama M; Steg PG; Dubois-Randé JL; Metzger JP; Tarragano F; Guermonprez JL; Drouet L;
    Am J Cardiol; 2003 Apr; 91(8):925-30. PubMed ID: 12686329
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Promise of combined low-molecular-weight heparin and platelet glycoprotein IIb/IIIa inhibition: results from Platelet IIb/IIIa Antagonist for the Reduction of Acute coronary syndrome events in a Global Organization Network B (PARAGON B).
    Mukherjee D; Mahaffey KW; Moliterno DJ; Harrington RA; Yadav JS; Pieper KS; Gallup D; Dyke C; Roe MT; Berdan L; Lauer MS; Mänttäri M; White HD; Califf RM; Topol EJ
    Am Heart J; 2002 Dec; 144(6):995-1002. PubMed ID: 12486423
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low-molecular-weight heparin should replace unfractionated heparin in the management of acute coronary syndromes.
    Zed PJ
    J Thromb Thrombolysis; 1999 Aug; 8(2):79-87. PubMed ID: 10436138
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patterns of use of heparins in ACS. Correlates and hospital outcomes: the Global Registry of Acute Coronary Events (GRACE).
    Klein W; Kraxner W; Hödl R; Steg PG; Budaj A; Gulba D; Sadiq I; van de Werf F; White K; Fox KA;
    Thromb Haemost; 2003 Sep; 90(3):519-27. PubMed ID: 12958622
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of low-molecular-weight heparin in invasive management of non-ST-elevation acute coronary syndromes.
    Moser LR; Kalus JS
    Ann Pharmacother; 2004 Dec; 38(12):2094-104. PubMed ID: 15536140
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anticoagulation for acute coronary syndromes: from heparin to direct thrombin inhibitors.
    Lepor NE
    Rev Cardiovasc Med; 2007; 8 Suppl 3():S9-17. PubMed ID: 17917621
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heparin versus placebo for non-ST elevation acute coronary syndromes.
    Andrade-Castellanos CA; Colunga-Lozano LE; Delgado-Figueroa N; Magee K
    Cochrane Database Syst Rev; 2014 Jun; 2014(6):CD003462. PubMed ID: 24972265
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of unfractionated and low molecular weight heparins on plasma levels of hemostatic factors in patients with acute coronary syndromes.
    Vila V; Martínez-Sales V; Réganon E; Peris E; Perez F; Ruano M; Aznar J
    Haematologica; 2001 Jul; 86(7):729-34. PubMed ID: 11454528
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized comparative study of using enoxaparin instead of unfractionated heparin in the intervention treatment of coronary heart disease.
    Chen JL; Chen J; Qiao SB; Guo YL; Wu YJ; Dai J; Yuan JQ; Qin XW; Yang YJ; Gao RL
    Chin Med J (Engl); 2006 Mar; 119(5):355-9. PubMed ID: 16542576
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of un-fractionated heparin and low molecular weight heparin on hospital mortality in patients with non ST elevation acute coronary syndrome (ACS).
    Angkasuwapala K; Ratanasumawong K; Ngarmukos T; Kehasukcharoen W; Boonsom W; Kamsa-ard S
    J Med Assoc Thai; 2007 Oct; 90 Suppl 1():109-14. PubMed ID: 18431893
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Unfractionated heparin and low molecular weight heparin for acute coronary syndromes--assessment of a Cochrane review].
    Husted SE; Nielsen HK
    Ugeskr Laeger; 2010 Sep; 172(37):2522-6. PubMed ID: 20836961
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.